VANCOUVER, Sept. 18, 2019 /CNW/ - Sirona Biochem Corp.
(TSX-V: SBM) (FSE: ZSB) (US-OTC:
SRBCF) ("Sirona") is excited to announce that it
has completed a definitive agreement with Rodan + Fields, LLC
("Rodan + Fields"), the leading skin care brand in
the United States1, for
the licensing and commercial sales of novel ingredient TFC-1067 to
brighten and even skin tone. Rodan and Fields will be the first to
market for a consumer product utilizing TFC-1067 in certain
countries including United
States.
Under the terms of the agreement, Sirona will receive an upfront
and milestone payments as well as on-going revenue in return for
the manufacture and supply of TFC-1067, a novel, new skin
brightening ingredient, for use by Rodan + Fields on a
non-exclusive basis and Rodan + Fields will launch a new product
incorporating the ingredient. Further details of this
agreement will remain confidential for strategic reasons. Both
Sirona and Rodan + Fields look forward to a mutually beneficial
long-term relationship.
"Sirona's board concluded that working on a non-exclusive basis
will enable us to advance, in parallel, on multiple global
partnerships. We are therefore continuing active partnering
discussions regarding TFC-1067. Ultimately, we will achieve maximum
commercial value by penetrating the numerous sales channels and
territories available. This will enable us to capture a larger
portion of the global skin lightening market with TFC-1067",
reports Dr. Howard Verrico, CEO of
Sirona Biochem.
The agreement also establishes regular meetings between Sirona's
and Rodan + Field's scientists to explore future collaborations on
new consumer products. This brings together the full spectrum of
expertise to take early stage concept through to an innovative
formulated product worthy of the Rodan + Fields skin care
philosophy.
Contract Research Organization (CRO) Roowin (www.roowin.com) has
developed a chemical process required for large scale manufacturing
of TFC-1067 and has now been instructed by Sirona to begin
manufacturing to fill anticipated orders for the product
launch.
"The commercial validation of our platform technology represents
a major milestone for Sirona's team. This agreement marks a first
step in the introduction of TFC-1067 into key markets and the
launch of TFC-1067 into the global market", added Dr. Verrico. "We
have worked through extensive due diligence and built a good
relationship with Rodan + Fields. We are very pleased to be working
with the number one skincare brand in the U.S.2 for the
launch of our innovative and superior skin brightening compound,
TFC-1067. Moreover, we are looking forward to update our
shareholders about our progress in China in due course."
"As a company committed to innovation, Rodan + Fields
continually seeks out novel and ground-breaking technologies.
We're excited to partner with Sirona to commercialize this highly
novel new molecule in an up-and-coming product release and deliver
the well-validated benefits to our consumer base", said Dr.
Simon Craw, Senior Director R&D
Business Development at Rodan + Fields. "Developing long-term
strategic relationships with biotech companies is part of Rodan +
Fields' DNA, and in Sirona we see an innovation-focused company we
can work closely with over the next several years", Dr Craw
continued.
About Rodan + Fields
Founded by Stanford-trained
dermatologists Dr. Katie Rodan and
Dr. Kathy Fields, Rodan + Fields was
launched in 2002 with the mission of giving consumers the best skin
of their lives. The brand is a result of the Doctors' belief that
healthy skin empowers people to feel confident. Born in the digital
era and designed to directly reach consumers where they live and
shop via mobile and social networks, Rodan + Fields is disrupting
the industry with its regimen-based skincare and powerful
Independent Consultant community.
For more information, please visit www.rodanandfields.com.
________________________
|
1
|
Source Euromonitor
International Limited; Beauty and Personal Care 2019 Edition,
retail value RSP terms; all channels, Skincare includes Sets &
Kits
|
2
|
Source Euromonitor
International Limited; Beauty and Personal Care 2019 Edition,
retail value RSP terms; all channels, Skincare includes Sets &
Kits
|
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery
company with a proprietary platform technology. Sirona specializes
in stabilizing carbohydrate molecules with the goal of improving
efficacy and safety. New compounds are patented for maximum revenue
potential.
Sirona's compounds are licensed to leading companies around the
world in return for licensing fees, milestone fees and ongoing
royalty payments. Sirona's laboratory, TFChem, is located in
France and is the recipient of
multiple French national scientific awards and European Union and
French government grants. For more information, please visit
www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Sirona Biochem cautions you that statements included in this
press release that are not a description of historical facts may be
forward-looking statements. Forward-looking statements are only
predictions based upon current expectations and involve known and
unknown risks and uncertainties. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of release of the relevant information, unless
explicitly stated otherwise. Actual results, performance or
achievement could differ materially from those expressed in, or
implied by, Sirona Biochem's forward-looking statements due to the
risks and uncertainties inherent in Sirona Biochem's business
including, without limitation, statements about: the progress and
timing of its clinical trials; difficulties or delays in
development, testing, obtaining regulatory approval, producing and
marketing its products; unexpected adverse side effects or
inadequate therapeutic efficacy of its products that could delay or
prevent product development or commercialization; the scope and
validity of patent protection for its products; competition from
other pharmaceutical or biotechnology companies; and its ability to
obtain additional financing to support its operations. Sirona
Biochem does not assume any obligation to update any
forward-looking statements except as required by law.
SOURCE Sirona Biochem Corp.